Regenxbio (RGNX) Misses Q4 EPS by 58c
Tweet
Share
E-mailGet Alerts RGNX Hot Sheet
Join SI Premium – FREE
Regenxbio (NASDAQ: RGNX) reported Q4 EPS of ($1.30), $0.58 worse than the analyst estimate of ($0.72). Revenue for the quarter came in at $30.34 million versus the consensus estimate of $59.28 million.
For earnings history and earnings-related data on Regenxbio (RGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Reiterates Buy Rating on Volkswagen AG (VOW:GR) (VWAGY)
- Kepler Cheuvreux Downgrades Volkswagen AG (VOW:GR) (VWAGY) to Hold
- UBS Upgrades H Lundbeck A/S (HLUNB:DC) (HLUYY) to Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
